S 44819

Drug Profile

S 44819

Alternative Names: S-44819

Latest Information Update: 09 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Servier
  • Class
  • Mechanism of Action GABA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 19 Dec 2016 Phase-II clinical trials in Stroke (In the elderly, In adults) in United Kingdom, Sweden, Spain, Poland, Netherlands, Hungary, Germany, Belgium, Australia, France (PO) (NCT02877615) (EudraCT2016-001005-16)
  • 14 Jun 2016 Servier plans a phase II trial for Stroke in United Kingdom
  • 18 Jan 2016 Preclinical trials in Stroke in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top